Clinical trial
"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in…
NCT00402012 · Pennington Biomedical Research Center, Other · Completed
Key facts
| NCT number | NCT00402012 |
|---|---|
| Title | "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM |
| Official title | Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM |
| Lead sponsor | Pennington Biomedical Research Center, Other |
| Collaborators | Takeda Pharmaceuticals North America, Inc. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Pioglitazone |
| Enrollment | 24 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Nov 22, 2006 |
| Last update posted | Dec 18, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: